+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Use of calcium hydroxylapatite (Radiesse) for facial augmentation

Use of calcium hydroxylapatite (Radiesse) for facial augmentation

Clinical Interventions in Aging 3(1): 161-174

Radiesse (Bioform Inc, USA) is a sterile, latex-free, non-pyrogenic, semi-solid, cohesive subdermal, injectable implant, whose principal component is synthetic calcium hydroxylapatite, a biocompatible material with over 20 years of use in medicine. The semi-solid nature of the product is created by suspending calcium hydroxylapatite microspheres of 25-45 microns diameter in a gel carrier of carboxymethylcellulose. The product has FDA approval for esthetic facial augmentation in the US. Such approval includes the long-lasting correction of moderate to severe facial wrinkles and folds and the treatment of facial fat loss due to immunodeficiency virus infection. Diverse facial regions can be injected in order to ameliorate or enhance some features: glabellar lines, subdermal support of the brows, malar and buccal fat pads, tear troughs, nasolabial folds, nose, lips, perioral region, marionette lines, oral commisures and chin among others, as well as saucerized acne scars. Other medical indications include nipple projection for nipple areolar reconstruction, urinary incontinence, vesicoureteral reflux, vocal cord augmentation, and use as a radiographic tissue marker. The average lasting result is from 12 to 18 months. Radiesse can be considered an effective soft-tissue filler for overall longevity, biocompatibility, and low rate of side effects.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 056795252

Download citation: RISBibTeXText

PMID: 18488886

DOI: 10.2147/cia.s2065

Related references

Evaluation of a calcium hydroxylapatite-based implant (Radiesse) for facial soft-tissue augmentation. Plastic and Reconstructive Surgery 118(3 Suppl): 22s-30s Discussion 31s-33s, 2006

Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plastic and Reconstructive Surgery 118(3 Suppl): 34s-45s, 2006

Hand augmentation with Radiesse (Calcium hydroxylapatite). Dermatologic Therapy 20(6): 385-387, 2007

Calcium hydroxylapatite facial filler (Radiesse): indications, technique, and results. Clinics in Plastic Surgery 33(4): 511-523, 2006

Anterior filler displacement following injection of calcium hydroxylapatite gel (Radiesse) for anophthalmic orbital volume augmentation. Ophthalmic Plastic and Reconstructive Surgery 28(5): 335-337, 2012

Long-lasting results with hydroxylapatite (Radiesse) facial filler. Plastic and Reconstructive Surgery 118(3 Suppl): 15s-21s, 2006

Calcium hydroxylapatite: Radiesse. Facial Plastic Surgery Clinics of North America 15(1): 85-90 Vii, 2007

Hand recontouring with calcium hydroxylapatite (Radiesse). Journal of Cosmetic Dermatology 8(1): 44-51, 2009

Injectable calcium hydroxylapatite microspheres (Radiesse). Facial Plastic Surgery 25(2): 100-105, 2009

Prospective 3D analysis of facial soft tissue augmentation with calcium hydroxylapatite. Journal of Cosmetic and Laser Therapy 19(5): 283-289, 2017

A 52-month summary of results using calcium hydroxylapatite for facial soft tissue augmentation. Dermatologic Surgery 34(Suppl. 1): S9, 2008

Correction of anophthalmic enophthalmos with injectable calcium hydroxylapatite (Radiesse). Ophthalmic Plastic and Reconstructive Surgery 23(4): 313-314, 2007

A novel solution for superficially placed calcium hydroxylapatite (Radiesse) in the inferior eyelid. Orbit 31(6): 431-432, 2012

The role of calcium hydroxylapatite (Radiesse) in nonsurgical aesthetic rejuvenation. Journal of Drugs in Dermatology 9(5): 446-450, 2010

Calcium hydroxylapatite (Radiesse): safety, techniques and pain reduction. Journal of Drugs in Dermatology 8(10 Suppl): S21-S23, 2009